Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Carroll, Jeffrey B ^a   Southwell, Amber L ^a   Graham, Rona K ^a   Lerch, Jason P ^b   Ehrnhoefer, Dagmar E ^a   Cao, Li Ping ^a   Zhang, Wei Ning ^a   Deng, Yu ^a   Bissada, Nagat ^a   Henkelman, R ^b   Hayden, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

caspase; Huntington's Disease; magnetic resonance imaging; neurodegeneration

Indexed keywords

CASPASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN SIZE; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DISEASE COURSE; DNA CLEAVAGE; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; LOCOMOTION; MALE; MAZE TEST; MOTOR ACTIVITY; MOUSE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; ROTAROD TEST; SWIMMING T MAZE; TASK PERFORMANCE;

MUS;

EID: 80051788879     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-59     Document Type: Article

References (66)

1. Huntington's disease. Walker F, Lancet 2007 369 9557 218 228 10.1016/S0140-6736(07)60111-1 17240289 (Pubitemid 46107685)
2. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group, Cell 1993 72 6 971 983 10.1016/0092-8674(93)90585- E 8458085 (Pubitemid 23110238)
3. Neuropathological classification of Huntington's disease. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP, J Neuropathol Exp Neurol 1985 44 6 559 577 10.1097/00005072-198511000-00003 2932539 (Pubitemid 16196286)
4. Caspase function in programmed cell death. Kumar S, Cell Death Differ 2007 14 1 32 43 10.1038/sj.cdd.4402060 17082813 (Pubitemid 44911892)
5. No death without life: vital functions of apoptotic effectors. Galluzzi L, Joza N, Tasdemir E, Maiuri MC, Hengartner M, Abrams JM, Tavernarakis N, Penninger J, Madeo F, Kroemer G, Cell Death Differ 2008 15 7 1113 1123 10.1038/cdd.2008.28 18309324 (Pubitemid 351850963)
6. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, et al. Cell Death Differ 2004 11 4 424 438 10.1038/sj.cdd.4401358 14713958 (Pubitemid 38489420)
7. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, et al. J Neurosci 2002 22 18 7862 7872 12223539 (Pubitemid 35379091)
8. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, Cattaneo E, Hackam A, Sharp A, Thornberry N, et al. J Biol Chem 2000 275 26 19831 19838 10.1074/jbc.M001475200 10770929 (Pubitemid 30441585)
9. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, McCutcheon K, Salvesen GS, Propp SS, Bromm M, et al. J Biol Chem 1998 273 15 9158 9167 10.1074/jbc.273.15.9158 9535906 (Pubitemid 28176206)
10. Proteolytic processing of the Alzheimer's disease amyloid precursor protein within its cytoplasmic domain by caspase-like proteases. Weidemann A, Paliga K, Dürrwang U, Reinhard FB, Schuckert O, Evin G, Masters CL, J Biol Chem 1999 274 9 5823 5829 10.1074/jbc.274.9.5823 10026204 (Pubitemid 29109238)
11. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, et al. Cell 1999 97 3 395 406 10.1016/S0092-8674(00)80748-5 10319819 (Pubitemid 29214595)
12. Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease. LeBlanc A, Liu H, Goodyer C, Bergeron C, Hammond J, J Biol Chem 1999 274 33 23426 23436 10.1074/jbc.274.33.23426 10438520 (Pubitemid 29388097)
13. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, et al. Proc Natl Acad Sci USA 2003 100 17 10032 10037 10.1073/pnas.1630428100 12888622 (Pubitemid 37087063)
14. Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. Young JE, Gouw L, Propp S, Sopher BL, Taylor J, Lin A, Hermel E, Logvinova A, Chen SF, Chen S, et al. J Biol Chem 2007 282 41 30150 30160 10.1074/jbc.M705265200 17646170 (Pubitemid 350035251)
15. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Li H, Zhu H, Xu CJ, Yuan J, Cell 1998 94 4 491 501 10.1016/S0092-8674(00)81590-1 9727492 (Pubitemid 28391865)
16. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC, The EMBO Journal 1999 18 19 5242 5251 10.1093/emboj/18.19.5242 10508158 (Pubitemid 29465575)
17. Caspase mechanisms. Salvesen GS, Riedl SJ, Adv Exp Med Biol 2008 615 13 23 10.1007/978-1-4020-6554-5-2 18437889
18. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, et al. Cell 2006 125 6 1179 1191 10.1016/j.cell.2006.04.026 16777606 (Pubitemid 43866195)
19. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, Hayden MR, Brain 2009 132 Pt 4 919 932 19224899
20. Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RWY, Vasuta OC, Graham RK, Hayden MR, et al. Neuron 2010 65 2 178 190 10.1016/j.neuron.2010.01. 008 20152125
21. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S, Carlson E, Sagi SA, Chevallier N, Jin K, et al. J Biol Chem 1999 274 13 8730 8736 10.1074/jbc.274.13.8730 10085113 (Pubitemid 29164670)
22. Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. Saganich MJ, Schroeder BE, Galvan V, Bredesen DE, Koo EH, Heinemann SF, J Neurosci 2006 26 52 13428 13436 10.1523/JNEUROSCI.4180-06.2006 17192425 (Pubitemid 46026474)
23. Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. Ellerby LM, Andrusiak RL, Wellington CL, Hackam AS, Propp SS, Wood JD, Sharp AH, Margolis RL, Ross CA, Salvesen GS, et al. J Biol Chem 1999 274 13 8730 8736 10.1074/jbc.274.13.8730 10085113 (Pubitemid 29164670)
24. beta-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, Greene LA, J Neurochem 2001 77 1 157 164 10.1046/j.1471-4159.2001.t01-1-00218.x 11279271 (Pubitemid 32245089)
25. Caspase-2 mediates neuronal cell death induced by beta-amyloid. Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K, Shelanski ML, J Neurosci 2000 20 4 1386 1392 10662829 (Pubitemid 30220418)
26. Multiple caspases are involved in beta-amyloid-induced neuronal apoptosis. Allen JW, Eldadah BA, Huang X, Knoblach SM, Faden AI, J Neurosci Res 2001 65 1 45 53 10.1002/jnr.1126 11433428 (Pubitemid 32605683)
27. Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Wang L, Miura M, Bergeron L, Zhu H, Yuan J, Cell 1994 78 5 739 750 10.1016/S0092-8674(94)90422-7 8087842
28. Induction of apoptosis by the mouse Nedd2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1 beta-converting enzyme. Kumar S, Kinoshita M, Noda M, Copeland NG, Jenkins NA, Genes Dev 1994 8 14 1613 1626 10.1101/gad.8.14.1613 7958843 (Pubitemid 24236241)
29. Alice in caspase land. A phylogenetic analysis of caspases from worm to man. Lamkanfi M, Declercq W, Kalai M, Saelens X, Vandenabeele P, Cell Death Differ 2002 9 4 358 361 10.1038/sj.cdd.4400989 11965488 (Pubitemid 34814616)
30. The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Xue D, Shaham S, Horvitz HR, Genes Dev 1996 10 9 1073 1083 10.1101/gad.10.9.1073 8654923 (Pubitemid 26152849)
31. Caspase-2 is localized at the Golgi complex and cleaves golgin-160 during apoptosis. Mancini M, Machamer CE, Roy S, Nicholson DW, Thornberry NA, Casciola-Rosen LA, Rosen A, J Cell Biol 2000 149 3 603 612 10.1083/jcb.149.3.603 10791974 (Pubitemid 30252394)
32. AlphaII-spectrin is an in vitro target for caspase-2, and its cleavage is regulated by calmodulin binding. Rotter B, Kroviarski Y, Nicolas G, Dhermy D, Lecomte M-C, Biochem J 2004 378 (Pt 1):161 168
33. Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. Panaretakis T, Laane E, Pokrovskaja K, Björklund A-C, Moustakas A, Zhivotovsky B, Heyman M, Shoshan MC, Grandér D, Mol Biol Cell 2005 16 8 3821 3831 10.1091/mbc.E04-10-0862 15917298 (Pubitemid 41077090)
34. Essential roles of the Bcl-2 family of proteins in caspase-2-induced apoptosis. Gao Z, Shao Y, Jiang X, J Biol Chem 2005 280 46 38271 38275 10.1074/jbc.M506488200 16172118 (Pubitemid 43853724)
35. Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways. McStay GP, Salvesen GS, Green DR, Cell Death Differ 2008 15 2 322 331 10.1038/sj.cdd.4402260 17975551
36. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR, Hum Mol Genet 2005 14 24 3823 3835 10.1093/hmg/ddi407 16278236 (Pubitemid 43020084)
37. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR, J Neurosci 2005 25 16 4169 4180 10.1523/JNEUROSCI.0590-05.2005 15843620 (Pubitemid 40563393)
38. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Slow EJ, van Raamsdonk J, Rogers DA, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang Y, et al. Hum Mol Genet 2003 12 13 1555 1567 10.1093/hmg/ddg169 12812983 (Pubitemid 36857303)
39. Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. O'Reilly LA, Ekert P, Harvey N, Marsden V, Cullen L, Vaux DL, Hacker G, Magnusson C, Pakusch M, Cecconi F, et al. Cell Death Differ 2002 9 8 832 841 10.1038/sj.cdd.4401033 12107826
40. Regional and cellular gene expression changes in human Huntington's disease brain. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, et al. Hum Mol Genet 2006 15 6 965 977 10.1093/hmg/ddl013 16467349 (Pubitemid 43338237)
41. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M, et al. J Neurosci 2005 25 43 9932 9939 10.1523/JNEUROSCI.3355-05.2005 16251441 (Pubitemid 41528031)
42. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, Hayden MR, Brain: a journal of neurology 2009 132 Pt 4 919 932
43. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. Southwell AL, Ko J, Patterson PH, J Neurosci 2009 29 43 13589 13602 10.1523/JNEUROSCI.4286-09.2009 19864571
44. Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function. Aron AR, Watkins L, Sahakian BJ, Monsell S, Barker RA, Robbins TW, J Cogn Neurosci 2003 15 5 629 642 10.1162/jocn.2003.15.5.629 12965037 (Pubitemid 36871877)
45. Executive and mnemonic functions in early Huntington's disease. Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW, Robbins TW, Brain 1996 119 Pt 5 1633 1645 8931586 (Pubitemid 26375733)
46. Exploratory activity, motor coordination, and spatial learning in Mchr1 knockout mice. Lalonde R, Qian S, Behav Brain Res 2007 178 2 293 304 10.1016/j.bbr.2007.01.006 17270288 (Pubitemid 46350787)
47. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR, J Neurol Neurosurg Psychiatr 1995 58 2 192 200 10.1136/jnnp.58.2.192 7876851
48. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. Southwell AL, Ko J, Patterson PH, J Neurosci 2009 29 43 13589 13602 10.1523/JNEUROSCI.4286-09.2009 19864571
49. Testicular degeneration in Huntington disease. Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersén A, Björkqvist M, Muir C, Mackenzie IR, Hammond GL, et al. Neurobiol Dis 2007 26 3 512 520 10.1016/j.nbd.2007.01.006 17433700 (Pubitemid 46756321)
50. Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington Disease. Carroll JB, Lerch JP, Franciosi S, Spreeuw A, Bissada N, Henkelman RM, Hayden MR, Neurobiol Dis 2011
51. High resolution three-dimensional brain atlas using an average magnetic resonance image of 40 adult C57Bl/6J mice. Dorr AE, Lerch JP, Spring S, Kabani N, Henkelman RM, NeuroImage 2008 42 1 60 69 10.1016/j.neuroimage.2008.03.037 18502665
52. Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's disease. Lerch JP, Carroll JB, Dorr A, Spring S, Evans AC, Hayden MR, Sled JG, Henkelman RM, NeuroImage 2008 41 2 243 251 10.1016/j.neuroimage.2008.02.019 18387826
53. Automated deformation analysis in the YAC128 Huntington disease mouse model. Lerch JP, Carroll JB, Spring S, Bertram LN, Schwab C, Hayden MR, Henkelman RM, NeuroImage 2008 39 1 32 39 10.1016/j.neuroimage.2007.08.033 17942324 (Pubitemid 350102212)
54. Automated deformation analysis in the YAC128 Huntington disease mouse model. Lerch JP, Carroll JB, Spring S, Bertram LN, Schwab C, Hayden MR, Mark Henkelman R, Neuroimage 2008 39
55. Brain structure in preclinical Huntington's disease. Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, Nopoulos PC, Biol Psychiatry 2006 59 1 57 63 10.1016/j.biopsych.2005.06.003 16112655 (Pubitemid 43005236)
56. The pattern of attentional deficits in Huntington's disease. Sprengelmeyer R, Lange H, Hömberg V, Brain 1995 118 Pt 1 145 152 7895000
57. Evidence for specific cognitive deficits in preclinical Huntington's disease. Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench-Constant C, Rubinsztein DC, Robbins TW, Sahakian BJ, Brain 1998 121 Pt 7 1329 1341 9679784 (Pubitemid 28327409)
58. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. Van Raamsdonk JM, Pearson J, Bailey CDC, Rogers DA, Johnson GVW, Hayden MR, Leavitt BR, J Neurochem 2005 95 1 210 220 10.1111/j.1471-4159. 2005.03357.x 16181425 (Pubitemid 41384439)
59. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, Honer WG, Hayden MR, Leavitt BR, Exp Neurol 2005 196 2 266 272 10.1016/j.expneurol.2005.07.021 16129433 (Pubitemid 41607814)
60. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Group HS, Neurology 2006 66 3 366 372 16476934
61. Presentation of 3D isotropic imaging data for optimal viewing. Henkelman RM, Baghdadi L, Sled JG, Magn Reson Med 2006 56 6 1371 1374 10.1002/mrm.21077 17075854 (Pubitemid 44865321)
62. High resolution three-dimensional brain atlas using an average magnetic resonance image of 40 adult C57Bl/6J mice. Dorr AE, Lerch JP, Kabani N, Henkelman RM, Neuroimage 2008 42 1 60 69 10.1016/j.neuroimage.2008.03.037 18502665
63. Automatic 3-D model-based neuroanatomical segmentation. Collins D, Holmes C, Peters T, Evans A, Human Brain Mapping 1995 3 3 190 208 10.1002/hbm. 460030304 (Pubitemid 3036541)
64. Morris water maze training induces changes in brain shape detectable by MRI. Lerch J, Yiu A, Bohbot V, Henkelman R, Josselyn S, Sled J, Society for Neuroscience 2007 104530
65. R: A Language and Environment for Statistical Computing. Team RDC, 2009
66. Regional and cellular gene expression changes in human Huntington's disease brain. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, et al. Hum Mol Genet 2006 15 6 965 977 10.1093/hmg/ddl013 16467349 (Pubitemid 43338237)